Ginkgo Results Presentation Deck

Update on M&A Activity We expect M&A to be an important strategic lever for Ginkgo, as we can acquire high potential technologies and deploy them at scale. Two deals recently announced: Project Beacon COVID-19 What: Project Beacon is a Boston-based social benefit organization focused on helping to increase the capacity, availability, accessibility, and affordability of COVID-19 testing. Why: Ability to bring on an experienced team and deepen relationship with Commonwealth of Massachusetts with minimal financial investment. When: Announced January 19, 2022 How: Strong, pre-existing relationship with Project Beacon made Concentric the acquirer of choice fgen What: FGen is a Swiss company specializing in ultra-high-throughput screening, using nanoliter reactor technology. Why: Enhances Ginkgo's cell screening and directed evolution capabilities. Technology can be broadly applied across many Ginkgo programs. When: Announced March 14, 2022 How: Multi-year partnership with FGen built trust and respect between the teams 41 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW

View entire presentation